Log in

NASDAQ:DOVADova Pharmaceuticals Insider Trades

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 11/12/2019)
Today's Range
Now: $28.04
50-Day Range
MA: $28.04
52-Week Range
Now: $28.04
Volume35,036 shs
Average Volume499,313 shs
Market Capitalization$807.55 million
P/E RatioN/A
Dividend YieldN/A

Insider Trades

Dova Pharmaceuticals (NASDAQ:DOVA) Insider Buying and Selling Activity

Insider Ownership Percentage: 60.30%

Insider Buying and Selling by Quarter

Dova Pharmaceuticals (NASDAQ DOVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2019David ZaccardelliCEOSell5,275$27.90$147,172.50
9/30/2019Jason HoittInsiderSell2,387$28.00$66,836.00
9/30/2019Kevin LaliberteVPSell3,696$28.00$103,488.00
9/25/2019Kevin LaliberteVPSell3,100$20.00$62,000.00
8/9/2019Paul B ManningDirectorBuy28,062$15.87$445,343.94  
7/31/2019Kevin LaliberteVPSell1,389$15.97$22,182.33  
7/15/2019Jason HoittInsiderSell7,580$15.26$115,670.80  
7/11/2019Life Sciences Maste PerceptiveMajor ShareholderBuy85,104$16.68$1,419,534.72  
7/5/2019Life Sciences Maste PerceptiveMajor ShareholderBuy50,000$16.46$823,000.00  
7/3/2019Life Sciences Maste PerceptiveMajor ShareholderBuy20,541$14.51$298,049.91  
7/2/2019David ZaccardelliCEOSell10,450$15.94$166,573.00  
7/1/2019Kevin LaliberteVPSell1,191$14.17$16,876.47  
7/1/2019Lee F Md Phd AllenInsiderSell1,957$14.19$27,769.83  
7/1/2019Mark W HahnCFOSell1,545$14.17$21,892.65  
7/1/2019Roger JeffsDirectorSell1,308$14.17$18,534.36  
6/28/2019Jason HoittInsiderSell2,387$13.81$32,964.47  
6/28/2019Life Sciences Maste PerceptiveMajor ShareholderBuy427,209$13.35$5,703,240.15  
4/8/2019Jason HoittInsiderSell2,387$8.77$20,933.99  
3/7/2019Paul B ManningDirectorBuy68,000$7.48$508,640.00  
12/20/2018David ZaccardelliCEOBuy10,000$6.07$60,700.00  
12/20/2018Paul B ManningDirectorBuy266,631$6.17$1,645,113.27  
8/14/2018Alex SapirCEOBuy21,700$22.83$495,411.00  
6/21/2018Steven M GoldmanDirectorBuy5,000$30.22$151,100.00  
6/11/2018Life Sciences Maste PerceptiveMajor ShareholderBuy19,700$29.36$578,392.00  
6/8/2018Life Sciences Maste PerceptiveMajor ShareholderBuy25,000$28.65$716,250.00  
6/7/2018Paul B ManningDirectorBuy27,000$28.42$767,340.00  
6/6/2018Life Sciences Maste PerceptiveMajor ShareholderBuy100,000$28.66$2,866,000.00  
6/5/2018Paul B ManningDirectorBuy120,000$26.17$3,140,400.00  
6/4/2018Life Sciences Maste PerceptiveMajor ShareholderBuy10,000$25.07$250,700.00  
8/16/2017Paul B ManningDirectorBuy25,870$22.30$576,901.00  
8/15/2017Steven M GoldmanDirectorBuy20,169$22.23$448,356.8781,158  
7/5/2017Alex SapirCEOBuy20,100$17.00$341,700.0020,100  
7/5/2017Kevin LaliberteVPBuy6,200$17.00$105,400.006,200  
7/5/2017Lee F Md Phd AllenInsiderBuy3,500$17.00$59,500.003,500  
7/5/2017Steven M GoldmanDirectorBuy72,000$17.94$1,291,680.0042,000  
(Data available from 1/1/2013 forward)
This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.